Cargando…

Author Correction: Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood

Detalles Bibliográficos
Autores principales:	Kariotis, Sokratis, Jammeh, Emmanuel, Swietlik, Emilia M., Pickworth, Josephine A., Rhodes, Christopher J., Otero, Pablo, Wharton, John, Iremonger, James, Dunning, Mark J., Pandya, Divya, Mascarenhas, Thomas S., Errington, Niamh, Thompson, A. A. Roger, Romanoski, Casey E., Rischard, Franz, Garcia, Joe G. N., Yuan, Jason X.-J., An, Tae-Hwi Schwantes, Desai, Ankit A., Coghlan, Gerry, Lordan, Jim, Corris, Paul A., Howard, Luke S., Condliffe, Robin, Kiely, David G., Church, Colin, Pepke-Zaba, Joanna, Toshner, Mark, Wort, Stephen, Gräf, Stefan, Morrell, Nicholas W., Wilkins, Martin R., Lawrie, Allan, Wang, Dennis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700755/ https://www.ncbi.nlm.nih.gov/pubmed/36433938 http://dx.doi.org/10.1038/s41467-022-33381-y

Ejemplares similares

Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
por: Kariotis, Sokratis, et al.
Publicado: (2021)

Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome
por: Rhodes, Christopher J., et al.
Publicado: (2020)

A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach
por: Errington, Niamh, et al.
Publicado: (2021)

Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?
por: Sofianopoulou, Eleni, et al.
Publicado: (2020)

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension
por: Rhodes, Christopher J., et al.
Publicado: (2017)

Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?
por: Peacock, Andrew J., et al.
Publicado: (2020)

Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment
por: Toshner*, Mark, et al.
Publicado: (2014)

Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy
por: Wilkins, Martin R., et al.
Publicado: (2021)

Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension
por: Jones, Rowena J., et al.
Publicado: (2022)

Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension
por: Condliffe, Robin, et al.
Publicado: (2012)

The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease
por: Hadinnapola, Charaka, et al.
Publicado: (2015)

Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension
por: Swietlik, Emilia M., et al.
Publicado: (2021)

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension
por: Toshner, Mark R., et al.
Publicado: (2010)

Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study
por: Karia, Nina, et al.
Publicado: (2023)

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
por: Toshner, Mark, et al.
Publicado: (2022)

Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension
por: Soon, Elaine, et al.
Publicado: (2011)

Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival
por: Schwiening, Max, et al.
Publicado: (2022)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

The prognostic ability of cardiac output determined by inert gas rebreathing technique in pulmonary hypertension
por: Robertson, Lucy, et al.
Publicado: (2022)

Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling
por: Pickworth, Josephine, et al.
Publicado: (2017)

Altered Macrophage Polarization Induces Experimental Pulmonary Hypertension and Is Observed in Patients With Pulmonary Arterial Hypertension
por: Zawia, Amira, et al.
Publicado: (2020)

Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension
por: Hernández-Sánchez, Jules, et al.
Publicado: (2017)

Acute lung injury after balloon pulmonary angioplasty results in a similar haemodynamic response and possible clinical advantage at follow‐up
por: Rodgers, Matthew S., et al.
Publicado: (2022)

A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension
por: Bunclark, Katherine, et al.
Publicado: (2021)

Author's reply
por: Pepke-Zaba, Joanna
Publicado: (2012)

EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study
por: Lewis, Robert A., et al.
Publicado: (2021)

Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension
por: Swietlik, Emilia M., et al.
Publicado: (2020)

Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension
por: Howard, Luke S.G.E., et al.
Publicado: (2013)

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
por: Gräf, Stefan, et al.
Publicado: (2018)

Balloon pulmonary angioplasty outcomes in patients previously treated by pulmonary endarterectomy surgery are inferior to those of inoperable patients
por: Kirkby, Louise C., et al.
Publicado: (2023)

Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Lifting the fog in intermediate-risk (submassive) PE: full dose, low dose, or no thrombolysis?
por: Bhamani, Amyn, et al.
Publicado: (2019)

A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension
por: Arnold, Nadine D., et al.
Publicado: (2019)

Inhibition of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension
por: Hameed, Abdul G., et al.
Publicado: (2012)

Isolation and characterisation of human pulmonary microvascular endothelial cells from patients with severe emphysema
por: Mackay, Laura S, et al.
Publicado: (2013)

Long-term effect of azithromycin in bronchiolitis obliterans syndrome
por: Gan, C.Tji-Joong, et al.
Publicado: (2019)

Soluble P-Selectin and von Willebrand Factor Rise in Healthy Volunteers Following Non-exertional Ascent to High Altitude
por: Turton, Helena A., et al.
Publicado: (2022)

The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations
por: Dunmore, Benjamin J., et al.
Publicado: (2013)

A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation
por: Corris, Paul A, et al.
Publicado: (2015)

(18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study
por: Hagan, Guy, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_de6cim9houq271bvouqii4e01d